Clinical Trial

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to generate hypotheses regarding the safety, efficacy, and immunological impact of cladribine tablets after treatment with natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (active SPMS).
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2019-11-22; most recent amendment 2025-12-04.
Status change: Recruiting → Active, Not Recruiting 2022-09-30
Status change: Not Yet Recruiting → Recruiting 2020-02-19
Trial Details
NCT Number NCT04178005
Lead Sponsor University of Texas Southwestern Medical Center
Collaborators: EMD Serono
Conditions Multiple Sclerosis
Enrollment 40 participants
Start Date 2020-02-19
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-08